Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 and Boostrix in Healthy Non-Pregnant Women
NCT04138056Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2019
- Primary completion
- Feb 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV) (5 arms), sponsored by GSK. Primary endpoints: Percentage of Subjects With Any Solicited Local Adverse Event, Percentage of Subjects With Any Solicited General Adverse Event and 4 more. Started Nov 2019; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04138056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04138056.